India's Drug Regulator Tightens Pharma Quality Control
India's DCGI orders nationwide inspections of small pharma units as WHO flags toxic cough syrups. MSMEs struggle to meet new Schedule M compliance deadline of January 2026.
Category : Search result: pharma industry
Indian Pharma Units Face Closure Over GMP Non-Compliance
DCGI directs state authorities to enforce strict GMP compliance by December 31, 2025. Delhi, Himachal Pradesh, Uttarakhand already taking action against non-compliant manufacturers.
DCGI Orders Global Pharma Standards Implementation by Jan 2026
India's drug regulator DCGI mandates global manufacturing standards for all pharma companies by January 2026. State regulators ordered to begin inspections immediately. Read about the strict compliance requirements.
Sun Pharma: US Tariff Clarity & Q2 FY26 Outlook
Sun Pharma investors await Q2 FY26 results with cautious optimism as US tariff clarity emerges. Discover how import duties and market dynamics could impact India's pharmaceutical giant.
Indian Pharma Soars with Record US Generic Drug Profits
Indian pharmaceutical companies are reporting exceptional earnings driven by US generic drug sales, leading to major fundraising initiatives for expansion into medtech and wellness sectors.
AstraZeneca Q3 Profit Jumps 77% to $2.53 Billion
British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.
Piramal Pharma Bets on US Biopharma Funding Revival
Piramal Pharma anticipates significant growth as US biopharma funding shows recovery signs, with CDMO business poised for major expansion.
Solara Pharma Q2 Loss: ₹10 Crore Amid Challenges
Solara Active Pharma Sciences faces challenging quarter with ₹10 crore net loss despite revenue growth. Discover the operational challenges and management's recovery strategy.
Sun Pharma Q2 Profit Rises 2.5% to ₹3,118 Crore
India's pharmaceutical giant Sun Pharma reports steady Q2 growth with 9% revenue increase while navigating US market challenges. Key insights from their latest earnings report.
IBM to Cut Thousands of Jobs in Major Restructuring
IBM becomes the latest tech giant to announce massive workforce reductions, planning to cut thousands of jobs globally as the technology sector's restructuring continues.
Chetan Bhagat: Bollywood Is Fundamentally Insecure Industry
Best-selling author Chetan Bhagat reveals why Bollywood operates on insecurity and warns against seeking genuine friendships in the film industry. Exclusive insights on survival tactics.
Navin Fluorine Shares Surge 22% in 3 Sessions
Discover why Navin Fluorine International shares skyrocketed 22% in just three trading sessions. Expert analysis reveals the key drivers behind this chemical sector powerhouse's impressive rally and what investors should watch next.
SRK rescued Dharma when Karan Johar's dad was dying
Exclusive revelation about how Shah Rukh Khan rescued Dharma Productions by rejecting Mahesh Bhatt's film when Karan Johar's father was critically ill. Viveck Vaswani shares untold Bollywood story.
Commercial Vehicle Sales Boom in October: Infrastructure Push Drives Recovery
India's commercial vehicle industry witnesses broad-based recovery in October driven by government infrastructure projects and festive season logistics demand, signaling strong economic revival.
Q2 Results Today: Sun Pharma, Grasim, Britannia Earnings
Market eyes Wednesday's Q2 earnings bonanza as pharma giant Sun Pharma, Grasim Industries, and FMCG major Britannia declare results. Get complete analysis and investor expectations.
3 Hot Stocks: Grasim, Aurobindo Pharma, City Union Bank
Religare Broking's Ajit Mishra reveals 3 promising stocks for short-term gains. Discover technical analysis and price targets for Grasim, Aurobindo Pharma, and City Union Bank in this exclusive market insight.
Hot Stocks: Oil India, Aurobindo Pharma, Latent View Analysis
Get expert stock market insights from Jigar Patel of Anand Rathi as he reveals why Oil India, Aurobindo Pharma, and Latent View Analytics present compelling short-term opportunities for Indian investors.
Nexperia Warning Deepens Crisis for Global Carmakers
Global automotive industry faces renewed supply chain turmoil as Dutch semiconductor giant Nexperia warns customers of serious production challenges, potentially worsening the ongoing chip shortage crisis.
Health Biotech Expands Global Presence at CPhI Frankfurt
Indian biopharmaceutical leader Health Biotech Limited makes waves at CPhI Frankfurt 2025, showcasing innovative products and forging international partnerships to strengthen its global market position.
Niner Pharma Expands R&D with 125 New Peptide Molecules
Chandigarh-based Niner Pharma announces massive R&D expansion with 125 novel peptide molecules targeting wellness and cosmetic innovation, positioning India as global leader in peptide research.
Cipla Shares Fall 4% After Q2 Results
Cipla's stock faced significant pressure after Q2 FY2025 results revealed margin pressures despite revenue growth. Discover the key factors behind the 4% decline and what analysts are saying about the pharmaceutical giant's future prospects.
India's Bakery Sector Eyes ASEAN Expansion via Jakarta Talks
Indian bakery industry prepares for major ASEAN expansion as key trade discussions culminate in Jakarta. Discover how Indian baked goods are set to conquer Southeast Asian markets.
US Push for Affordable Biotech Drugs: India's Opportunity
Federal health officials are accelerating efforts to bring cheaper biotech drugs to market, potentially transforming treatment access and creating new opportunities for Indian pharmaceutical companies.
India Bans Fraudulent Pharma Licenses in Major Reform
India implements sweeping regulatory reforms to combat fraudulent pharmaceutical manufacturing licenses, enhancing drug safety standards for domestic and international markets including US and EU.
Bollywood's Pay Gap: Makeup Artists Earn ₹1L/Day
Shocking revelations about Bollywood's budget allocation show hair and makeup teams enjoy first-class travel and 5-star hotels while screenwriters receive meager payments, exposing the industry's skewed priorities.
Hiten Tejwani: 22-hour work days, dozed off driving
Popular TV actor Hiten Tejwani reveals extreme work conditions in Indian television industry - 22-hour shifts for a month, earning just ₹1 lakh, and dangerous exhaustion that led to falling asleep at wheel.
Mukul Agrawal's ₹200 Cr Pharma Stock Bet Revealed
Discover why prominent investor Mukul Agrawal is betting big on a small-cap pharma company with massive growth potential. Get exclusive insights into his latest portfolio move and what it means for retail investors.
Dr. Reddy's Legacy: Transforming Indian Pharma
Discover how Dr. Anji Reddy's visionary journey from generics to innovative drug research positioned India as a global pharmaceutical powerhouse and continues to inspire future generations.
Bangladeshi generic drug slashes rare disease treatment cost by 96%
In a revolutionary healthcare development, Bangladesh's Beximco Pharma launches affordable generic version of lifesaving rare disease drug, dramatically reducing treatment costs from crores to lakhs for patients across South Asia.
Sigachi Q2: Profit Halves, Revenue Down 19%
Sigachi Industries faces turbulent quarter with net profit crashing to ₹10.5 crore amid significant revenue decline. What's behind the pharmaceutical giant's disappointing performance?
Page 1 of 4